Clinical Trials News,

Janssen Receives Positive CHMP Opinion Recommending Expanded Use of Imbruvica®▼(ibrutinib) in Two Indications in Europe

BEERSE, Belgium--(BUSINESS WIRE)--The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended broadening the existing marketing authorisation for Imbruvica® (ibrutinib) in two indications. One recommendation is for the use of ibrutinib in combination with obinutuzumab in adult patients with previously untreated chronic lymphocytic leukaemia (CLL).1 The second i

Business Wire Health: Clinical Trials News

14:48

Biodesix to Acquire Oncimmune in the United States

BOULDER, Colo.--(BUSINESS WIRE)--Biodesix to acquire Oncimmune in the United States. Acquisition includes CLIA lab and lung nodule malignancy risk test.

Business Wire Health: Clinical Trials News

14:00

Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes

NEW YORK--(BUSINESS WIRE)--<a href="https://twitter.com/search?q=%24BMY&src=ctag" target="_blank">$BMY</a>--Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes

Business Wire Health: Clinical Trials News

13:59